Kolexia
Le Tourneau Christophe Oncologie médicale
Le Tourneau Christophe
Oncologie médicale
Clcc Institut Curie
Paris, France
530 Activités
2 K Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Carcinomes Carcinome épidermoïde Carcinome épidermoïde de la tête et du cou Tumeurs de la tête et du cou Récidive tumorale locale Tumeurs du sein Métastase tumorale Tumeurs du col de l'utérus Tumeurs du poumon

Collaborateurs

Voir plus
Delord Jean-Pierre
Delord Jean-Pierre
Institut Universitaire du Cancer Toulouse Oncopole, Toulouse, France
Bieche Ivan
Bieche Ivan
Institut Curie, Saint-Cloud, France
Borcoman Edith
Borcoman Edith
Clcc Institut Curie, Paris, France
Sablin Marie-Paule
Sablin Marie-Paule
Clcc Institut Curie, Paris, France

Industries

Voir plus
MSD
32 collaboration(s)
Dernière en 2023
Roche
31 collaboration(s)
Dernière en 2023
Seagen
7 collaboration(s)
Dernière en 2023
Nanobiotix
5 collaboration(s)
Dernière en 2023

Dernières activités

Voir plus
IMMUNONET: A Multicenter, Open-label, Proof of Concept Phase II Aiming to Assess the Clinical and Biological Activity of Anti-netrin-1 (NP137) as Add on Therapy in Patients With Advanced/Metastatic Solid Tumors Treated by Standard Immunotherapies
Essai Clinique (NETRIS Pharma)   06 mars 2024
Phase III Xevinapant (Debio 1143) and Radiotherapy in Resected LA SCCHN, High Risk, Cisplatin-ineligible Participants (XRAY VISION): A Randomized, Double-blind, Placebo-controlled, 2-arm Phase III Study to Assess Efficacy and Safety of Xevinapant and Radiotherapy Compared to Placebo and Radiotherapy for Demonstrating Improvement of Disease-free Survival in Participants With Resected Squamous Cell Carcinoma of the Head and Neck, Who Are at High Risk for Relapse and Are Ineligible for High-dose Cisplatin (XRAY VISION)
Essai Clinique (Emd Serono)   05 mars 2024
A Study of SGN-PDL1V in Advanced Solid Tumors: A Phase 1 Study of SGN-PDL1V in Advanced Solid Tumors
Essai Clinique (Seagen)   01 mars 2024
A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors: Phase 1/2 Dose Escalation and Cohort Expansion Study Evaluating MCLA-158 (Petosemtamab) as Single Agent or in Combination in Advanced Solid Tumors
Essai Clinique (Merus N.V.)   01 mars 2024
Reframing sepsis immunobiology for translation: towards informative subtyping and targeted immunomodulatory therapies.
The Lancet. Respiratory medicine   23 février 2024
Tumor mutational burden assessment and standardized bioinformatics approach using custom NGS panels in clinical routine.
BMC biology   20 février 2024
SHIVA02 - Evaluation of the Efficacy of Targeted Therapy Based on Tumor Molecular Profiling in Patients With Advanced Cancer Using Each Patient as Its Own Control
Essai Clinique (Institut Curie)   15 février 2024
First-in-human Phase I to Evaluate PEP-010 as Single Agent and in Combination With Paclitaxel or With Gemcitabine (CleverPeptide): Dose Escalation, First-in-human Clinical Trial to Evaluate the Safety, Pharmacokinetics and Preliminary Antitumor Activity of PEP-010, Administered as Single Agent and in Combination With Paclitaxel or With Gemcitabine in Patients With Metastatic Solid Cancer
Essai Clinique (Institut Curie)   15 février 2024
Residual ANTXR1+ myofibroblasts after chemotherapy inhibit anti-tumor immunity via YAP1 signaling pathway.
Nature communications   12 février 2024
MOST plus: A Two-period, Multicenter, Randomized, Open-label, Phase II Study Evaluating the Clinical Benefit of a Maintenance Treatment Targeting Tumor Molecular Alterations in Patients With Progressive Locally-advanced or Metastatic Solid Tumors
Essai Clinique (Centre Léon-Bérard)   09 février 2024